Akiyama Noboru, Naruse Keiko, Kobayashi Yasuko, Nakamura Nobuhisa, Hamada Yoji, Nakashima Eitaro, Matsubara Tatsuaki, Oiso Yutaka, Nakamura Jiro
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Japan.
J Mol Cell Cardiol. 2008 Aug;45(2):326-32. doi: 10.1016/j.yjmcc.2008.04.006. Epub 2008 Apr 25.
Small GTPase Rho and Rho-kinase, the target protein of Rho, play an important role in atherosclerosis. In diabetic macroangiopathy, one of the major pathogenic changes is the migration of vascular smooth muscle cells (SMCs). Platelet-derived growth factor (PDGF) is known to stimulate the migration of SMCs. In the current study, we have investigated the involvement of the Rho/Rho-kinase pathway in the increased migration of cultured human aortic SMCs under a high glucose condition. PDGF stimulated the activation and the protein level of Rho. The protein level of PDGF receptor-beta (PDGFR-beta) was increased under the high glucose condition concomitant with the increased protein level and activation of Rho. The increased protein level and activity of Rho were suppressed by an anti-PDGF neutralizing antibody or a PDGFR-beta inhibitor, AG1433, under the high glucose condition. Furthermore, high glucose significantly increased the migration of SMCs. A specific inhibitor of Rho-kinase, Y-27632, or anti-PDGF neutralizing antibody inhibited increased migration of SMCs under the high glucose condition. The protein levels of Rho were increased in aortae of diabetic rats, which were abolished by the treatment of Imatinib, the inhibitor of PDGFR. These observations indicate that the upregulation of the PDGFR-beta / Rho / Rho-kinase pathway increases the migration of SMCs under the high glucose condition. The inhibition of Rho/Rho-kinase may be a new target for the treatment of diabetic macroangiopathy.
小GTP酶Rho及Rho的靶蛋白Rho激酶在动脉粥样硬化中起重要作用。在糖尿病大血管病变中,主要的病理变化之一是血管平滑肌细胞(SMC)的迁移。已知血小板衍生生长因子(PDGF)可刺激SMC迁移。在本研究中,我们调查了Rho/Rho激酶途径在高糖条件下培养的人主动脉SMC迁移增加中的作用。PDGF刺激Rho的激活及蛋白水平。在高糖条件下,PDGF受体-β(PDGFR-β)的蛋白水平升高,同时Rho的蛋白水平和激活也增加。在高糖条件下,抗PDGF中和抗体或PDGFR-β抑制剂AG1433可抑制Rho蛋白水平和活性的增加。此外,高糖显著增加了SMC的迁移。Rho激酶的特异性抑制剂Y-27632或抗PDGF中和抗体可抑制高糖条件下SMC迁移的增加。糖尿病大鼠主动脉中Rho的蛋白水平升高,而PDGFR抑制剂伊马替尼治疗可消除这种升高。这些观察结果表明,PDGFR-β/Rho/Rho激酶途径的上调在高糖条件下增加了SMC的迁移。抑制Rho/Rho激酶可能是治疗糖尿病大血管病变的新靶点。